由 sufang 在 五, 12/05/2014 – 10:12 發表 Pre-published IBPR Meeting
杏國Syncore (DBPR204, DBPR 104)
健亞Genovat (DBPR108, T2DM)
中天(Microbio)
cKIT, IDO1, IDH1, 大分子
COE of New Drug Discovery
- Success in clinical trials and regulation approval
- Drug discovery engine
- Team of excellent investigators
- Mentor/coaching/networking
Triangular relationship (Target, Drug, Disease)
- PK/PD correlation
- Biomarkers
- Translational model
TNFa 關節炎 Huber??
DBPR110: NS5A/HCV infection
DBPR211: 夏克山、明秀 CB1/T2DM antigonist (peripheral) 2015Q4
DBPR112: EGFR (irreversable)/NSCLC 2015Q4
DBPR114: Multi-target kinase, PanCA, Liver, Gastric Ca 2017 Q2 (此藥剛倍NRPB approved? 興邦)
Work-in-progress (WIP)
c-Kit/Flt3 drug resistant GIST/AML
Zn-DPA-SN38: small molecule, PS會翻出來, solide tumor CRC (鄒倫)
IDO1: Solid tumor/CRC (伍素瑩、明秀、夏克山、翁紹華)
Multiple kinase (PO) DBPR114 之延伸, 目標為口服. Solid tumor.
GA (glutaminase 2? GLS2?) MM, NHL (李秀珠)
Opioid AAM/chronic pain
CXCR4 (克山) Hematopoietic stem cell mobilization
MRSA drug resistant SA infection (2016)
Future direction:
–SM (small molecules) drug discovery
–Biologics drug discovery
*Therapeutic antibodies
*Antibody drug conjugates
–Novel therapeutic paltforms
*SBDD (structure based drug design)/computational/informatics
*PDX (translational pharmacology models)
*protein engineering platform
–Actively seeking internal/external collaborations
NICR, IPHS, NIIDV
–大份子
- R-Spondin 3/CRC 徐祖安 Competitive Intelligence
- VEGFR2/Solid tumor NICR
- NTRS1 -> EGFR link; NSCLC (105年政策額度)
- Adipopectin (日本人有一篇paper) 這是和侯明峰一樣的東西嗎?/TZDM
#1由 sufang 在 五, 12/12/2014 – 10:43 發表。
2014/05 與石泉所長雙邊會議
Notes from (1) 石泉所長雙邊會議 (05/2014) (2) chat with 素菁、靜娟
•鄒倫 李季珠: GA, Glutaminase inhibitor
•葉燈光: DMPK
•翁紹華: 化學合成、IDO1 inhibitor
•靜娟:
•Tki: EGFR, AURKA, AURKB, IDO1, FLT3, c-Kit
•DBPR114
•老鼠model <-> clinical
•Alimta
•預配方, pre-formulation
•success rate: phase 1,2,3 (50% x 50% x70%=17.5%)
•藍始榮、龔一泰
•Prof 楊宗德
•Immune therapy: PL-D1/CD274, IDO1
•glycoprotein
•PDX mouse
•stromal cells: immortalized fibroblast, MSC, PDMC
•HOK+carcinogen vs HOK+stromal cells+carcinoge vs HOK+cancer cells+carcinogen
•transwell to collect paracrine
•IDO1, Kyneurine assays (DiO, DiI?)
•CXCL1, 2, 3 (=Gro-a, b, g)
•MLR: mixed-lymphocyte reaction
•J.I 2013, Hsu, Su-Ching paper
•363, 442